Danielle Wing Lam Ng1, Ava Kwong2, Dacita Suen2, Miranda Chan3, Amy Or3, Siuman Simon Ng4, Chi Chung Foo2, Brenna F S Fielding5, Wendy W T Lam1. 1. Centre for Psycho-Oncological Research and Training, Division of Behavioural Sciences, School of Public Health, The University of Hong Kong, Hong Kong. 2. Department of Surgery, The University of Hong Kong, Hong Kong. 3. Department of Surgery, Kwong Wah Hospital, Hong Kong Hospital Authority, Hong Kong. 4. Department of Surgery, The Chinese University of Hong Kong, Hong Kong. 5. Department of Emergency Medicine, Royal Hampshire County Hospital, Winchester, UK.
Abstract
OBJECTIVE: Fear of cancer recurrence (FCR) represents a chronic burden for many cancer survivors. We determined FCR prevalence and potential correlates, specifically metacognitive styles and neuroticism among Chinese cancer survivors with breast or colorectal cancer. METHODS: This study included 285 Chinese patients with breast (N = 173) and colorectal (N = 112) cancers at 8-week postsurgery. Participants completed a set of baseline questionnaires evaluating FCR (Fear of Cancer Recurrence Inventory-Short Form [FCRI-SF]), metacognition (Metacognitions Questionnaire-30), and neuroticism (Eysenck Personality Questionnaire). Scores of 13 to 21 were indicative of subclinical FCR on the FCRI-SF. Scores greater than or equal to 22 indicated clinically significant levels of FCR. Fully adjusted multinomial logistic regressions identified correlates of subclinical and clinically significant FCR. RESULTS: Respectively, 26.0% (n = 74) and 11.2% (n = 32) achieved scores indicating subclinical and clinically significant FCR. Expressing significantly more positive (OR = 1.21, P = .003) and negative (OR = 1.19, P = .005) beliefs about worry was associated with a higher likelihood of reporting subclinical FCR. Both higher neuroticism (OR = 1.28, P = .003) and more negative beliefs about worry (OR = 1.19, P = 0.035) were associated with an increased likelihood of experiencing clinically significant FCR. CONCLUSIONS: Positive and negative metacognitions may play an important role in the development of subclinical FCR. In particular, negative metacognition and neuroticism may elevate FCR from subclinical to a clinical level. The findings give insight into the identification of cancer survivors with subclinical or clinical FCR and aid the development of interventions aimed at changing metacognitive beliefs in order to manage FCR.
OBJECTIVE: Fear of cancer recurrence (FCR) represents a chronic burden for many cancer survivors. We determined FCR prevalence and potential correlates, specifically metacognitive styles and neuroticism among Chinese cancer survivors with breast or colorectal cancer. METHODS: This study included 285 Chinese patients with breast (N = 173) and colorectal (N = 112) cancers at 8-week postsurgery. Participants completed a set of baseline questionnaires evaluating FCR (Fear of Cancer Recurrence Inventory-Short Form [FCRI-SF]), metacognition (Metacognitions Questionnaire-30), and neuroticism (Eysenck Personality Questionnaire). Scores of 13 to 21 were indicative of subclinical FCR on the FCRI-SF. Scores greater than or equal to 22 indicated clinically significant levels of FCR. Fully adjusted multinomial logistic regressions identified correlates of subclinical and clinically significant FCR. RESULTS: Respectively, 26.0% (n = 74) and 11.2% (n = 32) achieved scores indicating subclinical and clinically significant FCR. Expressing significantly more positive (OR = 1.21, P = .003) and negative (OR = 1.19, P = .005) beliefs about worry was associated with a higher likelihood of reporting subclinical FCR. Both higher neuroticism (OR = 1.28, P = .003) and more negative beliefs about worry (OR = 1.19, P = 0.035) were associated with an increased likelihood of experiencing clinically significant FCR. CONCLUSIONS: Positive and negative metacognitions may play an important role in the development of subclinical FCR. In particular, negative metacognition and neuroticism may elevate FCR from subclinical to a clinical level. The findings give insight into the identification of cancer survivors with subclinical or clinical FCR and aid the development of interventions aimed at changing metacognitive beliefs in order to manage FCR.
Authors: Xavier Torres; Ana Menjivar; Eva Baillès; Teresa Rangil; Isabel Delgado; Mireia Musquera; David Paredes; Montserrat Martínez; Núria Avinyó; Carmen Vallés; Laura Cañas; Dolores Lorenzo; Anna Vila-Santandreu; Raquel Ojeda; Emma Arcos; Erika De Sousa-Amorim; Antón Fernández; James R Rodrigue Journal: Transplant Direct Date: 2021-01-15
Authors: Yvonne L Luigjes-Huizer; Nina M Tauber; Gerry Humphris; Nadine A Kasparian; Wendy W T Lam; Sophie Lebel; Sébastien Simard; Allan Ben Smith; Robert Zachariae; Yati Afiyanti; Katy J L Bell; José A E Custers; Niek J de Wit; Peter L Fisher; Jacqueline Galica; Sheila N Garland; Charles W Helsper; Mette M Jeppesen; Jianlin Liu; Roxana Mititelu; Evelyn M Monninkhof; Lahiru Russell; Josée Savard; Anne E M Speckens; Sanne J van Helmondt; Sina Vatandoust; Nicholas Zdenkowski; Marije L van der Lee Journal: Psychooncology Date: 2022-04-07 Impact factor: 3.955
Authors: Fiona A Lynch; Lynda Katona; Michael Jefford; Allan Ben Smith; Joanne Shaw; Haryana M Dhillon; Steve Ellen; Jo Phipps-Nelson; Julia Lai-Kwon; Donna Milne; Lahiru Russell; Victoria Dax; Justine Diggens; Holly Kent; Alison Button-Sloan; Jane Elliott; Mark Shackleton; Hayley Burridge; Maria Ftanou Journal: J Clin Med Date: 2020-09-14 Impact factor: 4.241